ACL Digital strengthens position with Symbiance acquisition

ACL Digital has acquired US-based contract research organisation (CRO) Symbiance to strengthen its position as a global end-to-end clinical research and data CRO solutions provider.

The acquisition also enhances ACL Digital's life sciences portfolio by incorporating specialised expertise in pharmacovigilance, medical writing, biostatistics, data standardisation, clinical data management and statistical programming.

ACL Digital CEO Ramandeep Singh said: "The acquisition aligns with our growth strategy, enhancing our capabilities and delivering patient-centric, transformative solutions that exceed the standards of the life sciences industry.

"Together, we are positioned to accelerate innovation and drive operational efficiency for our clients. Moreover, ACL Digital's AI-powered offerings, combined with Symbiance's deep clinical research domain expertise, will enable us to meet the industry's AI transformation needs, empowering organisations to adopt intelligent, data-driven solutions that lead to improved outcomes."

With the acquisition, ACL Digital will also be able to drive digital transformation for biotech, pharmaceutical and medical device companies worldwide.

ACL Digital sales and operations senior vice-president Sreejith Narayanan said: "Symbiance has built a strong reputation in the US with its consistent focus on quality and delivery. Their success reflects the expertise of their leadership and the calibre of their team.

“This acquisition further underscores ACL Digital’s commitment to advancing as a global leader in digital solutions for clinical research. Together, we are strengthening our position in the life sciences and CRO space while enabling our customers to stay future-ready."

Symbiance president and CEO Ilango Ramanujam said the company’s 'people + product' delivery model, supported by tools and AI-driven analytics, will enhance ACL Digital's capabilities and service offerings to serve its present and future clients.

"ACL Digital strengthens position with Symbiance acquisition" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

View Comments